Key result
Macrotroponin occurs in ~2% of at-risk older adults and drives persistently elevated cTnI for years.
Why the study?
Macrotroponin may artefactually elevate cardiac troponin I levels, potentially misleading clinicians and causing inappropriate investigation and management.
Cohort (n=3,156)
Macrotroponin is present in approximately 2% of an older community cohort and causes persistently elevated troponin levels for years, highlighting the importance of its recognition to prevent unnecessary cardiac investigations.
Answers are grounded in this paper and cite their sources.
May warrant consideration for macrotroponin interference in unexplained persistent cTnI elevations; leaves open prevalence and impact in broader cohorts.
BACKGROUND: Cardiac troponin I (cTnI) is a biomarker for myocardial injury. However, macrotroponin, a complex of cTnI and endogenous cardiac troponin autoantibodies, may artefactually elevate cTnI levels with potential to mislead clinicians, leading to inappropriate investigation and management. AIM: To examine the prevalence and trajectory of macrotroponin in participants of the prospective community-based SCreening Evaluation of the Evolution of New Heart Failure (SCREEN-HF) study cohort. METHODS: Inclusion criteria were age ≥ 60 years with one or more self-reported ischaemic or other heart diseases, irregular or rapid heart rhythm, cerebrovascular disease, renal impairment or treatment for hypertension or diabetes for ≥2 years. Exclusion criteria were known heart failure or cardiac abnormality on echocardiography or other imaging. A cutoff residual cTnI activity ≤20% after polyethylene glycol precipitation was used to detect macrotroponin in plasma samples with cTnI levels above the sex-specific 99th percentile reference limits. RESULTS: Of 3156 SCREEN-HF participants with one or more cTnI measurements, 64 (2%) had macrotroponin. Among 2243 participants with two or more cTnI measurements, cTnI levels with macrotroponin were dynamic, although most elevated cTnI levels with macrotroponin at baseline remained elevated (14 of 16 men, 9 of 11 women) for several years during follow-up. CONCLUSIONS: Elevated cTnI levels with macrotroponin remained elevated for several years in asymptomatic individuals in this community-based cohort. While interpreting elevated cTnI levels in the clinical context, recording macrotroponin as a diagnosis could alert clinicians to possible artefactual elevation of cTnI levels during subsequent clinical presentation and avoid inappropriate investigation and management.
No takes yet. Share an insight, caveat, or question.
Campbell et al. (2026) conducted a cohort in Cardiovascular risk factors without known heart failure (n=3,156). Macrotroponin was evaluated on Prevalence of macrotroponin. Macrotroponin was present in 2% of older adults with cardiovascular risk factors, and elevated cTnI levels with macrotroponin remained elevated for several years during follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: